Back to results
US 12,269,798 B2Granted
Second generation GRP94-selective inhibitors
AssigneeUniversity of Kansas
InventorsBrian S. J. Blagg, Vincent Matthew Crowley
Life of this patent
Estimating the term…
Abstract
The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.
Claims24
A compound of Formula I
- or a pharmaceutically acceptable salt thereof, wherein
- X1 is Cl or F;
- X2 is CH2 or O;
- R1, R2, R4, R5, and R6 are each independently H, alkoxy, hydroxyl, thiol, or halo;
- and
- R3 is H, alkoxy, amino, hydroxyl, thiol, or halo.
3 more elements
A compound of Formula III
- or a pharmaceutically acceptable salt thereof, wherein
- X3 is Cl or F;
- X4 is CH2 or O;
- and
- R7 is alkoxy, hydroxyl, or halo.
2 more elements
Dependencies are inferred from the claim text.